XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 56.91

Change

0.00 (0.00)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.30 (-1.12%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.55 (-1.07%)

USD 114.12B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.94 (+0.16%)

USD 99.24B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.03B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.85 (-0.77%)

USD 59.61B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.16 (-1.06%)

USD 54.27B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.13 (+0.13%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.10 (+0.09%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.03 (-0.35%)

USD 40.33B
0ZC:F Zscaler Inc

+0.56 (+0.32%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.48% 66% D+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.48% 66% D+ 66% D+
Trailing 12 Months  
Capital Gain 16.65% 47% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.65% 48% F 57% F
Trailing 5 Years  
Capital Gain 72.69% 83% B 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.69% 83% B 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 10.68% 75% C 70% C-
Dividend Return 10.68% 73% C 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.71% 62% D 87% B+
Risk Adjusted Return 99.74% 96% N/A 96% N/A
Market Capitalization 0.85B 72% C 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike